1 The eect of reboxetine, a novel antidepressant drug that potently and selectively inhibits neuronal noradrenaline (NA) uptake, on brain extracellular monoamines was studied by microdialysis. 2 Fifteen mg kg 71 i.p. reboxetine raised extracellular NA in the frontal cortex (by 242%) and dorsal hippocampus (by 240%). 3 Idazoxan (1 mg kg 71 s.c.), given 60 min after 15 mg kg 71 reboxetine, markedly potentiated the eect on extracellular NA in the frontal cortex (by 1580%) and dorsal hippocampus (by 1360%), but had no eect by itself. 4 Twenty-four hours after the last injection of a chronic schedule (15 mg kg 71 i.p. once daily for 14 days) reboxetine had no eect on basal extracellular concentrations of NA in the dorsal hippocampus and a challenge dose of reboxetine (15 mg kg 71 ) raised extracellular NA similarly in rats treated chronically with reboxetine (by 353%) and saline (by 425%). 5 Ten and 20 mg kg 71 i.p. clonidine dose-dependently reduced hippocampal extracellular NA similarly in rats given chronic reboxetine (by 32% and 57%) and saline (by 42% and 56%). 6 Extracellular concentrations of dopamine and 5-HT in the striatum were similar in rats treated chronically with reboxetine and saline. A challenge dose of reboxetine (15 mg kg
Introduction
Most antidepressant drugs alleviate depression only after a few weeks, presumably because adaptive neuronal changes are necessary for their bene®cial eects. Recent studies with selective 5-HT reuptake inhibitors (SSRIs) have shown that their eect on extracellular 5-HT in terminal regions is attenuated by their simultaneous ability to activate somatodendritic 5-HT 1A receptors by increasing endogenous 5-HT in the raphe region (Adell & Artigas, 1991; Invernizzi et al., 1991; Hjorth & Auerbach, 1994; Arborelius et al., 1996) . Somatodendritic 5-HT 1A receptors are desensitized after chronic treatment with SSRIs and this facilitates their eects on extracellular 5-HT in terminal regions (Invernizzi et al., 1994; Rutter et al., 1994) . The slow increase in serotonergic transmission in these regions may help explain why the bene®cial eects of SSRIs take so long to appear.
Microdialysis studies with cocaine (Thomas et al., 1994) and desipramine (Mateo et al., 1998) suggested that cortical noradrenaline (NA) release was modulated by a 2 -adrenoceptors in the locus coeruleus. Electrophysiological studies suggested that presynaptic a 2 -adrenoceptors become subsensitive during long-term treatment with desipramine (McMillen et al., 1980; Lacroix et al., 1991) , but there is no evidence that chronic treatment with NA uptake inhibitors facilitates their eect on extracellular NA in terminal regions in the brain by desensitizing inhibitory a 2 -autoreceptors.
Reboxetine is a novel antidepressant drug that potently and selectively inhibits NA uptake (K i values in nM are eight for NA, 1070 for 5-HT and 410,000 for DA; Montgomery, 1999) ; unlike tricyclic antidepressant drugs, it has no appreciable action on muscarinic cholinergic and a 1 -adrenergic receptors (Riva et al., 1989) . The main objectives of the present study were: (1) to prove that blockade of a 2 -adrenoceptors by idazoxan increases the eect of reboxetine on extracellular NA in some terminal regions of the rat brain; (2) to examine whether chronic treatment with reboxetine has more eect on extracellular concentrations of NA in a brain terminal region than a single injection, in analogy with the eects of long-term treatment with SSRIs on extracellular 5-HT; (3) to assess the sensitivity of a 2 -adrenoceptors regulating NA release by studying the ability of clonidine, an a 2 -adrenoceptor agonist, to reduce hippocampal extracellular NA in rats treated chronically with reboxetine and saline (4) to asses the selectivity of reboxetine's eects on the noradrenergic system after chronic treatment by examining how it aects extracellular dopamine (DA) and 5-HT in the striatum.
Methods

Animals
Male Sprague-Dawley rats (CD-COBS,Charles River, Italy) weighing between 170 and 350 g were used. They were housed at constant room temperature (22+28C) and relative humidity (60+5%), with a regular 12/12 h light/dark cycle. Food and water were available ad libitum. Procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national (D.L. n. 116, G.U., suppl. 40, 18 Febbraio 1992 , Circolare N8 8, G.U., 14 Luglio, 1994 and international laws and policies (EEC Council Directive 86/609, OJ L 358,1, Dec. 12, 1987;  Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) . All eorts were made to minimize suering and to limit the number of animals used in the experiments. Finally, the eects of reboxetine was studied on the extracellular concentrations of DA and 5-HT in the striatum of rats given reboxetine (15 mg kg 71 ) or saline (2 ml kg 71 ) i.p. once daily for 14 days. A challenge dose of 15 mg kg 71 i.p. reboxetine was given 24 h after the last injection.
Treatments
The reboxetine dose was selected on the basis of a previous study showing an ID 50 of 7.51 mg kg 71 for inhibiting NA uptake (Riva et al., 1989) . Preliminary experiments were done to select the dose of idazoxan with little or no eect on extracellular NA to facilitate investigating the interaction with reboxetine.
Drugs
Reboxetine methansulphonate (Pharmacia & Upjohn, Milano, Italy) and clonidine hydrochloride (Boehringer Ingelheim, Italy) were dissolved in saline and injected i.p.. Idazoxan hydrochloride (RBI, Natick, MA, U.S.A.) was dissolved in saline and injected s.c.. Doses are referred to the salt.
Microdialysis procedures
The day before the microdialysis experiment rats were deeply anaesthetized with an injection of 3 ml kg 71 i.p. equithesin (1.2 g pentobarbital, 5.3 g chloral hydrate, 2.7 g MgSO 4 , 49.5 ml propylene glycol, 12.5 ml ethanol and 58 ml distilled water). They were placed on a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, U.S.A.) and a vertical dialysis probe made of Cuprophan (Sorin Biomedica, Italy; 200 mm inner diameter with 3000 Da molecular weight cuto) essentially as described by Robinson & Wishaw, (1988) was implanted in the dorsal hippocampus (2 mm long) and frontal cortex (4 mm long) at the following stereotaxic coordinates (from bregma and skull surface): dorsal hippocampus, AP=73.3; V=74.2; L=+1.9; frontal cortex, AP=+4.2; V=75.5; L=+0.7 (Paxinos & Watson, 1982) . In rats given chronic reboxetine a horizontal probe made of Cuprophan was used to increase the sensitivity of NA assay in experiments in which a marked reduction of extracellular NA was expected. In fact, hippocampal basal levels of NA (fmol/40 ml) are approximately 23 and 3 respectively using the horizontal and vertical probes. The probes were positioned at the following stereotaxic coordinates: dorsal hippocampi AP=5.7, V=6.7 and striata AP=9.7, V=5.6 from the interaural line according to the atlas of Paxinos & Watson (1982) . A single horizontal dialysis probe was implanted in each rat whereas two vertical probes were implated in the frontal cortex and dorsal hippocampus of the same rat. The horizontal dialysis probe had a 7-mm long glue-free zone for the dorsal hippocampi, and two 4-mm zones with a 2-mm glued area in between for the two striata. Bilateral marks were made on the probes to help position them.
The rat's skull was exposed and two holes were made on the lateral surfaces at the level of the target area. Dialysis ®bres, held straight by tungsten wires inside, were inserted transversely into the brain so that the glue-free zones were exactly in the target areas. The tungsten wires were removed and stainless steel cannulas (22 gauge, about 12 mm long) were glued to the ends of the probe. To prevent clogging, a thin ®shing line (0.08 mm outer diameter) was inserted into the lumen immediately before the probe was cemented to the skull with dental cement. Finally, the skin was sutured and the rats were allowed to recover from surgery overnight, one per cage, with food and water ad libitum.
The day after the surgical procedure the dialysis probes were perfused with aCSF containing (mM): NaCl 145, CaCl 2 1.26, KCl 3, MgCl 2 1 at pH 7.4 with sodium phosphate buer, at a constant¯ow rate of 2 ml min 71 , using a microperfusion pump (CMA 100, CMA Microdialysis, Sweden). Samples were collected at 20-min intervals and directly injected into the highperformance liquid chromatography (HPLC) system with electrochemical detector for the assay. Rats were treated with drugs when a stable basal concentration of monoamines was obtained (usually 3 ± 4 h from the beginning of the experiment).
At the end of the experiments rats were deeply anaesthetized with chloral hydrate and killed by decapitation. The brains were immediately removed, frozen and sliced in 40-mm sections for examination of the probe track. Only rats with correct probe placement were considered in the results.
Analytical procedure
Extracellular concentrations of NA were measured using a high-performance liquid chromatograph (Coulochem 5100 A, ESA, Bedford, MA, U.S.A.) equipped with an analytical cell consisting of two in-series electrodes (mod. 5011). The ®rst electrode was set at 70.2 V and the second at +0.25 V. NA was read as the second electrode output signal. Separation was obtained using a reverse-phase column (Hypersil-ODS 5 mm, 12563.1 mm, Bischo). The mobile phase, consisting of (mM): citric acid 25, sodium acetate 24, sodium octyl sulphate 1.55, Na 2 EDTA 0.1 and 80 ml l 71 CH 3 OH, was pumped at a constant¯ow rate of 1 ml min 71 with a Constametric III pump (LDC/Milton Roy, Riviera Beach, FL, U.S.A.).
DA was separated through a 15064.6 mm column (Supelcosil LC18-DB, 5 mm, Supelco, Bellefonte, PA, U.S.A.) using a mobile phase containing 0.1 M sodium acetate, 0.34 mM sodium octyl sulphate, 0.1 mM Na 2 EDTA, 60 ml l 71 CH 3 OH, pH 4.2 with acetic acid. A constant¯ow rate of 1 ml min 71 was maintained by a Constametric 3200 pump (LDC/Milton Roy, Riviera Beach, FL, U.S.A.). DA was measured by a Coulochem II electrochemical detector equipped with a 5011 analytical cell. The ®rst electrode was set at +350 mV and the second at 7190 mV. DA was read as the second electrode output signal. 5-HT was measured as described by Invernizzi et al. (1992) .
Reagents were of analytical grade and were purchased from Merck (Bracco, Milan, Italy) or Sigma-Aldrich (Milan, Italy). 
Data calculation and statistics
Basal values of extracellular neurotransmitters were de®ned as the means of three consecutive stable samples before drug treatment and were expressed as fmol 40 ml 71 (not corrected for recovery).
The overall eects of reboxetine, idazoxan and their combination on extracellular NA were estimated from the area under the curve (AUC) calculated for each rat by subtracting the basal extracellular NA values from each concentration after drug administration over the interval 0 ± 180 min. The resulting data were compared by two-way ANOVA (factorial design) followed by Tukey's test for posthoc comparison of the single means. Basal values of rats treated chronically with saline or drugs were compared by Student's t-test.
The eects of a challenge i.p. dose of reboxetine or clonidine in rats chronically treated with saline or reboxetine was compared by analysis of variance for repeated measures (splitplot), with treatment (tr) as between-subject factor and time (t) as within-subject factor. When signi®cant eects were found, post-hoc comparisons were made by Tukey's test.
Results
Eect of idazoxan on reboxetine-induced rise of extracellular NA in the dorsal hippocampus and frontal cortex
Reboxetine (15 mg kg 71 ) cause a similar increase in extracellular NA in the dorsal hippocampus and frontal cortex by 240% (Figure 1 ) and 242% (Figure 2 ) respectively. The eect persisted until the end of the observation period (3 h after injection). The overall eect, estimated from the AUC, was signi®cant in both brain regions (P50.05, Tukey's test).
Idazoxan (1 mg kg
71
) by itself had no signi®cant eect in either region, but signi®cantly potentiated the increase of extracellular NA induced by reboxetine in the dorsal hippocampus (Fint (1, 22) =19.2, P50.001, two-way ANOVA) and frontal cortex (Fint (1,16) =9.0, P50.01, two-way ANO-VA). No signi®cant dierence was found between the eects of the idazoxan-reboxetine combination in the dorsal hippocampus and frontal cortex (Fint (1,24) =1.6, P40.05; two-way ANOVA). In rats given reboxetine+idazoxan, extracellular NA was maximally increased at 20 min after idazoxan by 1360% and 1580% respectively in the dorsal hippocampus and frontal cortex. The eect of idazoxan was relatively shortlasting since no dierences in extracellular NA were observed in rats given reboxetine+saline and reboxetine+idazoxan 100 min after injection of the a 2 -adrenoceptor antagonist.
Eect of reboxetine on extracellular concentrations of NA in the dorsal hippocampus of rats chronically treated with saline or reboxetine As shown in Figure 3 , 24 h after the last injection of a 14-day schedule with saline or 15 mg kg 71 reboxetine once daily the basal extracellular concentrations of NA in the dorsal hippocampus were no dierent in the two groups. A challenge dose of 15 mg kg 71 reboxetine signi®cantly raised extracellular NA in rats chronically treated with saline. The eect was signi®cant throughout the experiment (180 min). Reboxetine raised extracellular NA similarly in the dorsal hippocampus of animals treated chronically with the drug (Ftr (1,10) =0.8, P40.05; Ft (9,90) =14.7, P50.01; Ftrxt (9,90) =0.4, P40.05).
Eect of clonidine on extracellular concentrations of NA in the dorsal hippocampus of rats treated chronically with saline or reboxetine Administered 24 h after the last injection of the chronic schedule with reboxetine, 10 mg kg 71 clonidine signi®cantly reduced by about 40% extracellular NA in the dorsal hippocampus of rats given saline or reboxetine for 2 weeks (Figure 4a) . No signi®cant dierence in the eects of clonidine was found between the two experimental groups (Ftr (1,10) =0.0, P40.05; Ft (6,60) =6.5, P50.01; Ftr x t (6,60) =1.02, P40.05). A Eect of reboxetine on extracellular concentrations of DA and 5-HT in the striatum of rats chronically treated with saline or reboxetine Twenty-four hours after the last of the chronic injections with saline or 15 mg kg 71 reboxetine, basal extracellular concentrations of DA (Figure 5a ) or 5-HT ( Figure 5b) were not changed in the striatum in either group. The challenge dose of 15 mg kg 71 reboxetine did not aect extracellular DA (Ftr (1,11) =0.0, P40.05; Ft (9,99) =1.8, P40.05; Ftrxt (9,99) =0.1, P40.05). The challenge dose raised extracellular 5-HT in the striatum of rats chronically treated with saline or reboxetine, but with no signi®cant dierences between the two treatments (Ftr (1, 14) =0.1, P40.05; Ft (9,126) =7.1 P50.01; Ftrxt (9,126) =0.8, P40.05). The eect was signi®cant respectively 20 and 40 min after injection (P50.05, Tukey's test) in rats given chronic reboxetine and saline.
Discussion
It has been proposed that the therapeutic activity of SSRIs or selective inhibitors of NA reuptake may be improved by combining them with presynaptic receptor antagonists, to enhance the eects on the extracellular concentrations of their respective neurotransmitters in the brain (Artigas et al., 1996; Mateo et al., 1998) . Blockade of 5-HT 1A receptors does not enhance the eects of SSRIs on extracellular 5-HT to the same extent in all brain regions, the dorsal hippocampus being particularly insensitive (Invernizzi et al., 1997; Romero & Artigas, 1997) . In view of the proposed importance of the dorsal hippocampus for antidepressant activity (de Montigny et al., 1993) , we studied whether idazoxan modi®ed the eect of reboxetine on extracellular NA in the dorsal hippocampus in comparison with the eect in the frontal cortex. Microdialysis studies using local drug application have found that a 2 -adrenoceptor antagonists and desipramine caused greater increases in extracellular NA in hippocampus than in frontal cortex (Thomas & Holman, 1991; van Veldhuizen et al., 1994) . The dose of idazoxan used in the present study (1 mg kg 71 ) did not signi®cantly modify extracellular NA concentrations in hippocampus and frontal cortex whereas reboxetine caused a similar increase of extracellular NA in both regions. The present results with reboxetine are therefore at variance with those on desipramine showing a preferential eect on hippocampal NA release (Thomas & Holman, 1991) . Idazoxan enhanced the eect of reboxetine on extracellular NA to a similar extent in the frontal cortex and dorsal hippocampus. It seems therefore that blockade of a 2 -adrenoceptors increases the eect of a selective NA uptake inhibitor on brain extracellular NA more uniformly than previously obtained by combining presynaptic receptor antagonists with SSRIs.
The regional selectivity of SSRIs on extracellular 5-HT may be due to dierent densities of presynaptic 5-HT1A receptors (Weissman-Nanoupolos et al., 1985) in the two serotonergic cell groups, the dorsal and median nuclei, that innervate the frontal cortex and dorsal hippocampus respectively (Invernizzi et al., 1997) . Noradrenergic innnervation of the dorsal hippocampus and frontal cortex originates in the same cell group, the locus coeruleus (Lindvall & Bjorklund, 1974) , and this may explain why reboxetine alone or in combination with idazoxan have similar eects on extracellular NA in both regions.
a 2 -Adrenoceptors in the noradrenergic terminals also exert an inhibitory control on NA release (Maura et al., 1992) ; thus it is not clear to what extent these receptors in the locus coeruleus or in nerve terminals contributed to the eect of systemically administered idazoxan on the reboxetine-induced increase of extracellular NA in the two terminal regions. That somatodendritic a 2 -adrenoreceptors modulate the eect of selective NA uptake inhibitors on extracellular concentrations of NA in terminal regions is strongly suggested by a recent report that an a 2 -adrenoceptor antagonist injected into the locus coeruleus markedly enhanced the eect of desipramine on dialysate NA in the cingulate cortex (Mateo et al., 1998) .
Behavioural studies with clonidine have suggested that presynaptic a 2 -adrenoceptor function is attenuated by repeated treatment with various antidepressant drugs which increase synaptic levels of NA (Heal et al., 1991) . There is also some electrophysiological evidence that presynaptic a 2 -adrenoceptors are desensitized after long-term treatment with desipramine (McMillen et al., 1980; Lacroix et al., 1991) . We did in fact recently ®nd that 10 mg kg 71 desipramine i.p. increased extracellular NA more in the dorsal hippocampus of rats after once daily doses of 10 mg kg 71 desipramine for 14 days (manuscript in preparation). To examine whether the same happened with reboxetine, we gave rats 15 mg kg 71 reboxetine once daily for 14 days, with a challenge dose 24 h after the last dose. The challenge dose raised extracellular NA similarly in rats treated chronically with reboxetine and vehicle. Moreover, 10 and 20 mg kg 71 clonidine reduced hippocampal extracel- lular concentrantions of NA similarly in rats treated chronically with reboxetine and saline. It seems therefore that these treatment conditions did not induce signi®cant adaptive changes in noradrenergic transmission that could be re¯ected by changes in the drug's eect on extracellular NA after chronic treatment, probably due to the relatively rapid kinetics in rats . Adaptive changes may well occur during chronic treatment in depressed patients since reboxetine has a considerably longer plasma half-life in man than rats (Edwards et al., 1995) . In view of this, experiments are in progress using osmotic minipumps to deliver continuous, adequate levels of reboxetine to rats.
In a ®nal experiment, we studied the selective eect of reboxetine on the noradrenergic system by measuring extracellular concentrations of 5-HT and DA in the striatum under the same treatment conditions used for NA. Repeated doses of reboxetine did not aect the concentrations of 5-HT and DA in the rat striatum. A challenge dose of reboxetine had no eect on striatal DA but caused a slight, short-lasting increase of 5-HT at early times in vehicle and drug treated animals. An eect on 5-HT uptake mechanism is unlikely to have been involved since the selectivity ratio for inhibiting 5-HT and NA uptake is about 130 (Montgomery, 1999) . We can also exclude that an artifact of the injection was involved since an i.p. injection of saline did not signi®cantly modify striatal extracellular 5-HT (unpublished results). Perhaps, an increased noradrenergic transmission contributed to the eects on 5-HT, but further studies are needed to clarify whether reboxetine may cause signi®cant and stable changes in extracellular 5-HT in certain brain regions.
In conclusion, the present study has shown that blockade of a 2 -adrenoceptors by idazoxan signi®cantly increased the eect of reboxetine on extracellular NA in the frontal cortex and dorsal hippocampus of rats. Together with previous studies with desipramine (Mateo et al., 1998) , these ®ndings suggest that using reboxetine in combination with an a 2 -adrenoceptor antagonist may facilitate its antidepressant activity.
In our experimental conditions we obtained no evidence of adaptive changes in the noradrenergic system that could facilitate the eect of reboxetine on extracellular NA after long-term treatment. Experiments are in progress to investigate this further. Finally, for the ®rst time, to our knowledge, it has been shown that reboxetine is fairly selective for the noradrenergic system in awake rats, at least judging from extracellular 5-HT and DA levels in the striatum.
